JP2024508762A5 - - Google Patents
Info
- Publication number
- JP2024508762A5 JP2024508762A5 JP2023549819A JP2023549819A JP2024508762A5 JP 2024508762 A5 JP2024508762 A5 JP 2024508762A5 JP 2023549819 A JP2023549819 A JP 2023549819A JP 2023549819 A JP2023549819 A JP 2023549819A JP 2024508762 A5 JP2024508762 A5 JP 2024508762A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pharmaceutical composition
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150832P | 2021-02-18 | 2021-02-18 | |
| US63/150,832 | 2021-02-18 | ||
| US202163180896P | 2021-04-28 | 2021-04-28 | |
| US63/180,896 | 2021-04-28 | ||
| US202163226041P | 2021-07-27 | 2021-07-27 | |
| US63/226,041 | 2021-07-27 | ||
| US202163285785P | 2021-12-03 | 2021-12-03 | |
| US63/285,785 | 2021-12-03 | ||
| PCT/US2022/016840 WO2022178158A1 (en) | 2021-02-18 | 2022-02-17 | Anti-tl1a antibody compositions and methods of treatment in the lung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024508762A JP2024508762A (ja) | 2024-02-28 |
| JP2024508762A5 true JP2024508762A5 (enExample) | 2025-02-26 |
Family
ID=82931034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549819A Pending JP2024508762A (ja) | 2021-02-18 | 2022-02-17 | 抗ｔｌ１ａ抗体組成物及び肺における治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240336691A1 (enExample) |
| EP (1) | EP4294443A4 (enExample) |
| JP (1) | JP2024508762A (enExample) |
| KR (1) | KR20230158494A (enExample) |
| AU (1) | AU2022221712A1 (enExample) |
| BR (1) | BR112023016574A2 (enExample) |
| CA (1) | CA3207818A1 (enExample) |
| MX (1) | MX2023009681A (enExample) |
| TW (1) | TW202302640A (enExample) |
| WO (1) | WO2022178158A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| EP3969621A4 (en) | 2019-05-14 | 2023-01-25 | Prometheus Biosciences, Inc. | TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES |
| TW202600603A (zh) | 2019-10-24 | 2026-01-01 | 美商普羅米修斯生物科學股份有限公司 | 針對類-tnf配體1a (tl1a)之人類化抗體及其用途 |
| KR20250160371A (ko) * | 2023-02-17 | 2025-11-12 | 프로메테우스 바이오사이언시즈, 인크. | 항-tl1a 항체 조성물 및 피부 치료 방법 |
| WO2024173877A1 (en) * | 2023-02-17 | 2024-08-22 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the liver |
| WO2024173865A2 (en) * | 2023-02-17 | 2024-08-22 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the kidney |
| WO2024186859A2 (en) * | 2023-03-09 | 2024-09-12 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment for sarcoidosis |
| IL325993A (en) | 2023-08-11 | 2026-03-01 | Paragon Therapeutics Inc | TL1A binding proteins and methods of use |
| US12473370B2 (en) | 2023-10-03 | 2025-11-18 | Absci Corporation | TL1A associated antibody compositions and methods of use |
| WO2025160331A1 (en) | 2024-01-26 | 2025-07-31 | Futuregen Biopharmaceutical (Beijing) Co., Ltd. | Antibodies capable of specifically binding tl1a and use thereof |
| CN120590530A (zh) * | 2024-03-05 | 2025-09-05 | 帆礼生物技术(武汉)有限公司 | 靶向tl1a的抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1667730T3 (da) * | 2003-08-20 | 2013-09-23 | Univ Miami | Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom |
| US20090226435A1 (en) * | 2008-03-08 | 2009-09-10 | Sanjay Khare | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| WO2014106602A1 (en) * | 2013-01-02 | 2014-07-10 | Glenmark Pharmaceuticals S.A. | Antibodies that bind to tl1a and their uses |
| CN105814081B (zh) * | 2013-11-13 | 2021-02-02 | 辉瑞大药厂 | 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途 |
| TWI703158B (zh) * | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| MY191324A (en) * | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| US10626180B2 (en) * | 2017-04-20 | 2020-04-21 | Cedars-Sinai Medical Center | Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease |
| CN119735681A (zh) * | 2018-04-25 | 2025-04-01 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| EP3969621A4 (en) * | 2019-05-14 | 2023-01-25 | Prometheus Biosciences, Inc. | TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES |
| TW202600603A (zh) * | 2019-10-24 | 2026-01-01 | 美商普羅米修斯生物科學股份有限公司 | 針對類-tnf配體1a (tl1a)之人類化抗體及其用途 |
-
2022
- 2022-02-17 KR KR1020237031713A patent/KR20230158494A/ko active Pending
- 2022-02-17 WO PCT/US2022/016840 patent/WO2022178158A1/en not_active Ceased
- 2022-02-17 AU AU2022221712A patent/AU2022221712A1/en active Pending
- 2022-02-17 EP EP22756948.0A patent/EP4294443A4/en active Pending
- 2022-02-17 CA CA3207818A patent/CA3207818A1/en active Pending
- 2022-02-17 MX MX2023009681A patent/MX2023009681A/es unknown
- 2022-02-17 BR BR112023016574A patent/BR112023016574A2/pt unknown
- 2022-02-17 TW TW111105899A patent/TW202302640A/zh unknown
- 2022-02-17 JP JP2023549819A patent/JP2024508762A/ja active Pending
- 2022-02-17 US US18/546,947 patent/US20240336691A1/en active Pending